No Data
No Data
Chimerix Shares Top 52-week Highs, Company Plans FDA Submission of Cancer Drug Dordaviprone
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Trending Stocks Today | Chimerix Soars 162.42% Post-Market
Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Express News | Chimerix Inc - Potential Approval for Dordaviprone in Q3 2025
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
No Data
browny_440 : ICCT has some potential
WciStudios OP : just checked it out, picked up 2000 to try it out